Sun Pharmaceutical Industries Limited has issued a regulatory disclosure under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company has scheduled a meeting of its Board of Directors for Monday, 12 October 2026. The primary agenda for this meeting is to consider and approve the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs).
The proposed NCD issuance will be conducted on a private placement basis in one or more tranches. The aggregate amount for this issuance is specified as not exceeding INR 15,000 Crore (Indian Rupees Fifteen Thousand Crore only).
The board will also consider matters incidental and connected to this NCD issuance proposal.